semaglutide and cardiovascular outcomes in patients with type 2 diabetes Cardiac Trials | Lowering CV risk GLP1 agonism? This large trial showed both improved — which in combo with LEADER Trial Cardiovascular Events in Adults with
Description
Diarrhea affects up to 20% of semaglutide users during the first weeks of treatment
Among the non-insulinoma PanNETs, immunohistochemical insulin or proinsulin positive cases were categorized as Inspos, and both negative cases as Insneg
FDA Enforcement Actions and Safety Concerns In September 2025, the FDA issued over 50 warning letters to compounders marketing GLP-1 products as generic equivalents to FDA-approved drugs
Combining creatine with semaglutide is generally safe, but requires careful monitoring of kidney function and hydration
High protein, portion-controlled, ready in minutes
Compounded semaglutide typically begins reducing appetite within 3-7 days, with meaningful weight loss appearing around week 4
